GlassScriptPhysician profile
Ashton Davis
NPI 1356876544
$10,072.32
in general payments reported to CMS, 2019-2025
34 companies · $2,416 in 2025
The $2,416 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $973 · 2020: $515 · 2021: $1,050 · 2022: $1,754 · 2023: $1,537 · 2024: $1,826 · 2025: $2,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,485 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,485.26 |
| Education | $293.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,225.76 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,016.99 | 2019-2025 | |
| Janssen Biotech, INC. | $840.32 | 2019-2025 | Tremfya, Remicade, Stelara |
| Sun Pharmaceutical Industries INC. | $740.71 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $648.89 | 2020-2025 | Dupixent |
| Pfizer INC. | $580.64 | 2019-2025 | |
| Incyte Corporation | $564.21 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $425.66 | 2022-2025 | Nemluvio, Dysport, Epsolay |
| Lilly USA, LLC | $398.15 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $331.88 | 2021-2025 | Bimzelx |
| Leo Pharma INC. | $263.19 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $229.91 | 2022-2024 | Sotyktu |
| Almirall LLC | $204.54 | 2021-2025 | Seysara |
| Mallinckrodt Hospital Products INC. | $197.51 | 2024-2025 | Acthar |
| Amgen INC. | $167.00 | 2019-2025 | Otezla, Otezla |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $148.67 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $134.49 | 2021-2024 | Cabtreo, Arazlo |
| Arcutis Biotherapeutics, INC. | $127.92 | 2023-2025 | Zoryve |
| Kyowa Kirin, INC. | $122.66 | 2019 | |
| Dusa Pharmaceuticals, INC. | $121.37 | 2019 | |
| Janssen Scientific Affairs, LLC | $119.23 | 2021 | |
| Mayne Pharma Commercial LLC | $91.75 | 2022-2025 | |
| Dermavant Sciences, INC. | $87.28 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $50.30 | 2020 | |
| Journey Medical Corporation | $35.53 | 2022-2023 | |
| Beone Medicines USA, INC. | $31.71 | 2025 | Brukinsa |
| Organon LLC | $30.95 | 2025 | Vtama |
| Allergan, INC. | $28.80 | 2021 | |
| Revance Therapeutics, INC. | $28.70 | 2024 | Daxxify |
| Convatec INC. | $20.35 | 2024 | |
| Novo Nordisk INC | $15.31 | 2025 | Wegovy |
| Helsinn Therapeutics (U.S.), INC. | $14.95 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $14.27 | 2024 | Clindacin Etz |
| Avanir Pharmaceuticals, INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashton Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.